Close
New

Medscape is available in 5 Language Editions – Choose your Edition here.

 

anti-inhibitor coagulant complex (Rx)Brand and Other Names:Feiba NF, Feiba VH Immuno

 
 
 

Dosing & Uses

AdultPediatric

Dosage Forms & Strengths

powder for reconstitution

  • 500 units
  • 1000 units
  • 2500 units
more...

Hemophilia A & B

Prevention and control of spontaneous hemorrhage or bleeding during surgical interventions in hemophilia patients who have autoantibodies or alloantibodies to coagulation factors; also indicated for routine prophylaxis to prevent or reduce the frequency of bleeding episodes in patients with hemophilia A or B who have developed inhibitors

Prevention and control of bleeding

  • Joint hemorrhage: 50 units/kg IV q12hr; may increase to 100 units/kg q12hr; continue until signs of clinical improvement occur; not to exceed 200 mg/kg/day
  • Mucous membrane bleed: 50 units/kg IV q6hr, may increase to 100 units/kg q6hr for 2 doses maximum; not to exceed 200 units/kg/day
  • Soft tissue hemorrhage: 100 units/kg IV q12hr; not to exceed 200 units/kg/day
  • Severe hemorrhage (eg, CNS bleed): 100 units/kg IV q6-12hr; not to exceed 200 units/kg/day unless severity of hemorrhage justifies higher doses

Perioperative management

  • Preoperative: 50-100 units/kg IV once immediately prior to surgery
  • Postoperative: 50-100 units/kg IV q6-12hr until resolution of bleeding and healing is achieved

Routine prophylaxis

  • 85 units/kg IV every other day

Dosage Forms & Strengths

powder for reconstitution

  • 500 units
  • 1000 units
  • 2500 units
more...

Hemophilia A & B

Prevention and control of spontaneous hemorrhage or bleeding during surgical interventions in hemophilia patients who have autoantibodies or alloantibodies to coagulation factors; also indicated for routine prophylaxis to prevent or reduce the frequency of bleeding episodes in patients with hemophilia A or B who have developed inhibitors

Prevention and control of bleeding

  • Joint hemorrhage: 50 units/kg IV q12hr; may increase to 100 units/kg q12hr; continue until signs of clinical improvement occur; not to exceed 200 mg/kg/day
  • Mucous membrane bleed: 50 units/kg IV q6hr, may increase to 100 units/kg q6hr for 2 doses maximum; not to exceed 200 units/kg/day
  • Soft tissue hemorrhage: 100 units/kg IV q12hr; not to exceed 200 units/kg/day
  • Severe hemorrhage (eg, CNS bleed): 100 units/kg IV q6-12hr; not to exceed 200 units/kg/day unless severity of hemorrhage justifies higher doses

Perioperative management

  • Preoperative: 50-100 units/kg IV once immediately prior to surgery
  • Postoperative: 50-100 units/kg IV q6-12hr until resolution of bleeding and healing is achieved

Routine prophylaxis

  • 85 units/kg IV every other day
Next

Interactions

Interaction Checker

anti-inhibitor coagulant complex and

No Results

     
     activity indicator 
    No Interactions Found
    Interactions Found

    Contraindicated

      Serious - Use Alternative

        Significant - Monitor Closely

          Minor

            Sort by :  
             activity indicator 
            Previous
            Next

            Adverse Effects

            Frequency Not Defined

            Headache

            Lethargy

            Nausea

            Chest discomfort

            Chills

            Rash

            Urticaria

            Injection site pain

            Fever

            Flushing

            Hypotension

            Myocardial infarction

            Tachycardia

            Thromboembolic events

            Hypersensitivity reactions

            Previous
            Next

            Warnings

            Black Box Warnings

            Thrombotic and thromboembolic events have been reported during post-marketing surveillance following infusion, particularly following the administration of high doses and/or in patients with thrombotic risk factors

            Contraindications

            Treatment of bleeding occurences resulting from deficiencies in coagulation factors VIII or IX

            DIC

            Normal coagulation mechanisms present

            Cautions

            Neonates (risk of thrombosis and/or hepatitis)

            Risk of transmissible infectious disease from human plasma (rare)

            Possibility of transient hypofibrinogenemia in children

            Administer to pregnant patients only if benefits outweigh risks

            Caution in patiehts with hepatic Impairment

            Small amounts of factor VIII in the formulationi may cause an anamnestic response

            Avoid or delay use in patients receiving treatment with antifibrolytic agents

            Only use to control bleeding in patients with coagulation deficiencies

            Discontinue in case of severe hypersensitivity reactions

            Previous
            Next

            Pregnancy & Lactation

            Pregnancy Category: C

            Lactation: Not studied

            Pregnancy Categories

            A:Generally acceptable. Controlled studies in pregnant women show no evidence of fetal risk.

            B:May be acceptable. Either animal studies show no risk but human studies not available or animal studies showed minor risks and human studies done and showed no risk.

            C:Use with caution if benefits outweigh risks. Animal studies show risk and human studies not available or neither animal nor human studies done.

            D:Use in LIFE-THREATENING emergencies when no safer drug available. Positive evidence of human fetal risk.

            X:Do not use in pregnancy. Risks involved outweigh potential benefits. Safer alternatives exist.

            NA:Information not available.

            more...
            Previous
            Next

            Pharmacology

            Mechanism of Action

            Provides activated blood coagulation factors II, VII, IX and X from pooled human plasma

            May shorten the activated partial thromboplastin time of plasma containing factor VIII inhibitors

            Previous
            Next

            Administration

            IV Preparation

            Warm drug and diluent to room temp

            Reconstitute with SWI according to manufacturers directions

            Do not refrigerate, use promptly

            IV Administration

            Slow IV injection or IV infusion

            Feiba VH/Feiba NF

            • infusion rate not to exceed 2 U/kg/min
            • complete infusion within 3 hr of reconstitution
            Previous
            Next

            Images

            Previous
            Next

            Formulary

            FormularyPatient Discounts

            To view formulary information first create a list of plans. Your list will be saved and can be edited at any time.

            Adding plans allows you to:

            • View the formulary and any restrictions for each plan.
            • Manage and view all your plans together – even plans in different states.
            • Compare formulary status to other drugs in the same class.
            • Access your plan list on any device – mobile or desktop.

            The above information is provided for general informational and educational purposes only. Individual plans may vary and formulary information changes. Contact the applicable plan provider for the most current information.

            Tier Description
            1 This drug is available at the lowest co-pay. Most commonly, these are generic drugs.
            2 This drug is available at a middle level co-pay. Most commonly, these are "preferred" (on formulary) brand drugs.
            3 This drug is available at a higher level co-pay. Most commonly, these are "non-preferred" brand drugs.
            4 This drug is available at a higher level co-pay. Most commonly, these are "non-preferred" brand drugs or specialty prescription products.
            5 This drug is available at a higher level co-pay. Most commonly, these are "non-preferred" brand drugs or specialty prescription products.
            6 This drug is available at a higher level co-pay. Most commonly, these are "non-preferred" brand drugs or specialty prescription products.
            NC NOT COVERED – Drugs that are not covered by the plan.
            Code Definition
            PA Prior Authorization
            Drugs that require prior authorization. This restriction requires that specific clinical criteria be met prior to the approval of the prescription.
            QL Quantity Limits
            Drugs that have quantity limits associated with each prescription. This restriction typically limits the quantity of the drug that will be covered.
            ST Step Therapy
            Drugs that have step therapy associated with each prescription. This restriction typically requires that certain criteria be met prior to approval for the prescription.
            OR Other Restrictions
            Drugs that have restrictions other than prior authorization, quantity limits, and step therapy associated with each prescription.
            Add or Remove Plans
            Plans for
            Select State:
            Non-Medicare PlansMedicare Plans

            Select a box to add or remove a plan.

            Select a class to view formulary status for similar drugs

            Additional Offers
            Email to Patient

            From:

            To:

            The recipient will receive more details and instructions to access this offer.

            By clicking send, you acknowledge that you have permission to email the recipient with this information.

            Email Forms to Patient

            From:

            To:

            The recipient will receive more details and instructions to access this offer.

            By clicking send, you acknowledge that you have permission to email the recipient with this information.

            Previous
             
             
             
            All material on this website is protected by copyright, Copyright © 1994-2016 by WebMD LLC. This website also contains material copyrighted by 3rd parties.